Advertisement

Topics

Lung cancer OK for Tecentriq sets up showdown with Merck and BMS

06:56 EDT 19 Oct 2016 | PMLIVE

Broad label will aid Roche’s PD-L1 inhibitor in head-to-head NSCLC market-share battle

Original Article: Lung cancer OK for Tecentriq sets up showdown with Merck and BMS

NEXT ARTICLE

More From BioPortfolio on "Lung cancer OK for Tecentriq sets up showdown with Merck and BMS"

Quick Search
Advertisement
 

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...